120 related articles for article (PubMed ID: 9355169)
1. Effect of antidepressant therapy on health care utilization and costs in primary care.
Croghan TW; Lair TJ; Engelhart L; Crown WE; Copley-Merriman C; Melfi CA; Obenchain RL; Buesching DP
Psychiatr Serv; 1997 Nov; 48(11):1420-6. PubMed ID: 9355169
[TBL] [Abstract][Full Text] [Related]
2. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants.
Simon GE; VonKorff M; Heiligenstein JH; Revicki DA; Grothaus L; Katon W; Wagner EH
JAMA; 1996 Jun; 275(24):1897-902. PubMed ID: 8648870
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of initial antidepressant drug choice in a "real world" randomized trial.
Simon GE; Heiligenstein J; Revicki D; VonKorff M; Katon WJ; Ludman E; Grothaus L; Wagner E
Arch Fam Med; 1999; 8(4):319-25. PubMed ID: 10418538
[TBL] [Abstract][Full Text] [Related]
4. Economic appraisal of citalopram in the management of single-episode depression.
Sclar DA; Skaer TL; Robison LM; Galin RS
J Clin Psychopharmacol; 1999 Oct; 19(5 Suppl 1):47S-54S. PubMed ID: 10507508
[TBL] [Abstract][Full Text] [Related]
5. Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment.
Revicki DA; Simon GE; Chan K; Katon W; Heiligenstein J
J Fam Pract; 1998 Dec; 47(6):446-52. PubMed ID: 9866670
[TBL] [Abstract][Full Text] [Related]
6. Modelling the cost effectiveness of antidepressant treatment in primary care.
Revicki DA; Brown RE; Palmer W; Bakish D; Rosser WW; Anton SF; Feeny D
Pharmacoeconomics; 1995 Dec; 8(6):524-40. PubMed ID: 10160081
[TBL] [Abstract][Full Text] [Related]
7. Economic outcomes with antidepressant pharmacotherapy: a retrospective intent-to-treat analysis.
Sclar DA; Skaer TL; Robison LM; Galin RS; Legg RF; Nemec NL
J Clin Psychiatry; 1998; 59 Suppl 2():13-7. PubMed ID: 9559755
[TBL] [Abstract][Full Text] [Related]
8. Fluoxetine and imipramine: are there differences in cost-utility for depression in primary care?
Serrano-Blanco A; Suárez D; Pinto-Meza A; Peñarrubia MT; Haro JM;
J Eval Clin Pract; 2009 Feb; 15(1):195-203. PubMed ID: 19239602
[TBL] [Abstract][Full Text] [Related]
9. Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population.
Tournier M; Moride Y; Crott R; du Fort GG; Ducruet T
J Affect Disord; 2009 May; 115(1-2):160-6. PubMed ID: 18694602
[TBL] [Abstract][Full Text] [Related]
10. Acute medical costs of fluoxetine versus tricyclic antidepressants. A prospective multicentre study of antidepressant drug overdoses.
Revicki DA; Palmer CS; Phillips SD; Reblando JA; Heiligenstein JH; Brent J; Kulig K
Pharmacoeconomics; 1997 Jan; 11(1):48-55. PubMed ID: 10165526
[TBL] [Abstract][Full Text] [Related]
11. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis.
Hylan TR; Crown WH; Meneades L; Heiligenstein JH; Melfi CA; Croghan TW; Buesching DP
J Affect Disord; 1998 Jan; 47(1-3):71-9. PubMed ID: 9476746
[TBL] [Abstract][Full Text] [Related]
12. Long-term costs of treatment for depression: impact of drug selection and guideline adherence.
Crown WH; Treglia M; Meneades L; White A
Value Health; 2001; 4(4):295-307. PubMed ID: 11705297
[TBL] [Abstract][Full Text] [Related]
13. Geriatric depression, antidepressant treatment, and healthcare utilization in a health maintenance organization.
Fischer LR; Wei F; Rolnick SJ; Jackson JM; Rush WA; Garrard JM; Nitz NM; Luepke LJ
J Am Geriatr Soc; 2002 Feb; 50(2):307-12. PubMed ID: 12028213
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings.
Revicki DA; Brown RE; Keller MB; Gonzales J; Culpepper L; Hales RE
J Clin Psychiatry; 1997 Feb; 58(2):47-58. PubMed ID: 9062373
[TBL] [Abstract][Full Text] [Related]
15. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization.
Sclar DA; Robison LM; Skaer TL; Legg RF; Nemec NL; Galin RS; Hughes TE; Buesching DP
Clin Ther; 1994; 16(4):715-30; discussion 74. PubMed ID: 7982260
[TBL] [Abstract][Full Text] [Related]
16. Open trial study of a combined antidepressant (amitryptiline, perphenazine, diazepam) versus fluoxetine or imipramine in ambulatory depressed patients.
Diaz A; Fouilloux C; Ortiz S
Proc West Pharmacol Soc; 2002; 45():154-5. PubMed ID: 12434564
[No Abstract] [Full Text] [Related]
17. Prevalence and predictors of depression treatment in an international primary care study.
Simon GE; Fleck M; Lucas R; Bushnell DM;
Am J Psychiatry; 2004 Sep; 161(9):1626-34. PubMed ID: 15337653
[TBL] [Abstract][Full Text] [Related]
18. Costs associated with changes in antidepressant treatment in a managed care population with major depressive disorder.
Schultz J; Joish V
Psychiatr Serv; 2009 Dec; 60(12):1604-11. PubMed ID: 19952150
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.
Taneja C; Papakostas GI; Jing Y; Baker RA; Forbes RA; Oster G
Ann Pharmacother; 2012 May; 46(5):642-9. PubMed ID: 22550279
[TBL] [Abstract][Full Text] [Related]
20. Assessing the relationship between compliance with antidepressant therapy and employer costs among employees in the United States.
Birnbaum HG; Ben-Hamadi R; Kelley D; Hsieh M; Seal B; Kantor E; Cremieux PY; Greenberg PE
J Occup Environ Med; 2010 Feb; 52(2):115-24. PubMed ID: 20134337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
